Massimo Massagrande

Healthcare provider experiences in managing antibody-drug conjugate dosing adjustments due to nausea and vomiting: SABCS and ESMO survey findings.

Lee Steven Schwartzberg, Luca Licata, Giampaolo Bianchini, Eric J. Roeland et autres

e13108 Background: Antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) have revolutionized breast cancer (BC) treatment, delivering superior efficacy that allows for extended treatment durations. Nausea and vomiting (NV) are among the most frequent adverse effects associated with …

us, it, kr, jp, fr, de, ch (code pays fourni par la source)

436P Healthcare provider (HCP) perspectives on antibody-drug conjugate (ADC)-induced nausea and vomiting: Insights from an ESMO survey

Luca Licata, Giampaolo Bianchini, Yeon‐Hwan Park, Hope S. Rugo et autres

291P Perceptions of antibody drug conjugate (ADC)-induced nausea and vomiting: Results of a survey of healthcare providers at ESMO

Giampaolo Bianchini, Yeon‐Hwan Park, Hope S. Rugo, Luca Licata et autres

The breast cancer (BC) treatment landscape is evolving with the availability of new anticancer agents such as antibody drug conjugates (ADCs). Based on major antiemetic guidelines, patients (pts) receiving trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) are considered at high risk of …

it, kr, us, jp, fr, de, ch (code pays fourni par la source)

Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendations

Alberto Giovanni Leone, Raffaella Casolino, Dario Trapani, Rosalba Miceli et autres

Transgender and gender-diverse individuals experience substantial health disparities across the cancer care continuum. Despite well recognized unique healthcare needs, there are barriers in accessing cancer prevention and treatment services, influenced by disadvantages in key social-economic determinants of health which result in worse …

it, gb (code pays fourni par la source)

Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology

Alberto Giovanni Leone, Rosalba Miceli, Dario Trapani, Massimo Massagrande et autres

BACKGROUND: Transgender and gender-diverse (TGD) population represents an underserved group across the cancer care continuum. To assess the perspective of both oncology health care providers (OHPs) and TGD individuals in Italy, we conducted two national surveys: one among 2407 OHPs about their …

it, gb (code pays fourni par la source)